JP7278952B2 - 安定化された抗体タンパク質溶液 - Google Patents

安定化された抗体タンパク質溶液 Download PDF

Info

Publication number
JP7278952B2
JP7278952B2 JP2019546211A JP2019546211A JP7278952B2 JP 7278952 B2 JP7278952 B2 JP 7278952B2 JP 2019546211 A JP2019546211 A JP 2019546211A JP 2019546211 A JP2019546211 A JP 2019546211A JP 7278952 B2 JP7278952 B2 JP 7278952B2
Authority
JP
Japan
Prior art keywords
aqueous solution
antibody protein
antibody
protein
storage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019546211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508333A (ja
JP2020508333A5 (https=
Inventor
ジェゼク ジャン
ジェリング デビッド
Original Assignee
アレコル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレコル リミテッド filed Critical アレコル リミテッド
Publication of JP2020508333A publication Critical patent/JP2020508333A/ja
Publication of JP2020508333A5 publication Critical patent/JP2020508333A5/ja
Priority to JP2022208841A priority Critical patent/JP2023052088A/ja
Application granted granted Critical
Publication of JP7278952B2 publication Critical patent/JP7278952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2019546211A 2017-02-24 2018-02-23 安定化された抗体タンパク質溶液 Active JP7278952B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022208841A JP2023052088A (ja) 2017-02-24 2022-12-26 安定化された抗体タンパク質溶液

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1703063.6 2017-02-24
GBGB1703063.6A GB201703063D0 (en) 2017-02-24 2017-02-24 Stabilized antibody protein solutions
PCT/GB2018/050480 WO2018154319A1 (en) 2017-02-24 2018-02-23 Stabilized antibody protein solutions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022208841A Division JP2023052088A (ja) 2017-02-24 2022-12-26 安定化された抗体タンパク質溶液

Publications (3)

Publication Number Publication Date
JP2020508333A JP2020508333A (ja) 2020-03-19
JP2020508333A5 JP2020508333A5 (https=) 2021-04-08
JP7278952B2 true JP7278952B2 (ja) 2023-05-22

Family

ID=58544083

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019546211A Active JP7278952B2 (ja) 2017-02-24 2018-02-23 安定化された抗体タンパク質溶液
JP2022208841A Pending JP2023052088A (ja) 2017-02-24 2022-12-26 安定化された抗体タンパク質溶液

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022208841A Pending JP2023052088A (ja) 2017-02-24 2022-12-26 安定化された抗体タンパク質溶液

Country Status (5)

Country Link
US (1) US20200023062A1 (https=)
EP (2) EP4289443A3 (https=)
JP (2) JP7278952B2 (https=)
GB (1) GB201703063D0 (https=)
WO (1) WO2018154319A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
US20230041240A1 (en) * 2020-01-30 2023-02-09 Leukocare Ag Reduction of Adsorption
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
CN121002123A (zh) 2023-03-28 2025-11-21 住友化学株式会社 树脂组合物、成型体及树脂组合物的制造方法
CN117007791B (zh) * 2023-07-18 2024-08-09 广州市进德生物科技有限公司 一种辣根过氧化物酶偶联物稀释保存液

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530380A (ja) 2006-03-20 2009-08-27 ワイス タンパク質凝集を減少させるための方法
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
US20150335748A1 (en) 2005-08-05 2015-11-26 Amgen Inc. Pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335748A1 (en) 2005-08-05 2015-11-26 Amgen Inc. Pharmaceutical compositions
JP2009530380A (ja) 2006-03-20 2009-08-27 ワイス タンパク質凝集を減少させるための方法
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions

Also Published As

Publication number Publication date
WO2018154319A1 (en) 2018-08-30
EP4289443A2 (en) 2023-12-13
EP4289443A3 (en) 2024-02-28
US20200023062A1 (en) 2020-01-23
JP2020508333A (ja) 2020-03-19
JP2023052088A (ja) 2023-04-11
GB201703063D0 (en) 2017-04-12
EP3585820A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
JP7278952B2 (ja) 安定化された抗体タンパク質溶液
US12544445B2 (en) Methods for treatment using anti-α4β7 antibody
JP2023071755A (ja) 安定化された抗体溶液
EP2598167B1 (en) Stabilized aqueous antibody compositions
US11608357B2 (en) Stabilized antibody protein solutions
JP5937059B2 (ja) タンパク質含有製剤の安定化に有用な組成物及び方法
US20180327497A1 (en) Formulation for anti-alpha4beta7 antibody
JP5894154B2 (ja) タンパク質含有製剤の安定化のためのアルキルグリコシドを含む組成物及び方法
US20200069799A1 (en) Stabilized antibody protein solutions
CA2794864A1 (en) Compositions and methods useful for reducing the viscosity of protein-containing formulations
US12016922B2 (en) Stabilized aqueous antibody compositions
AU2018258676A1 (en) N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
US20230277453A1 (en) Stabilized antibody protein solutions
US20230414753A1 (en) Stabilized antibody protein solutions
HK1184379B (en) Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
HK1225982A1 (zh) 包含离子性液体的液体蛋白质制剂
HK1216842B (zh) 对於稳定含有蛋白质的制剂有用的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221226

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230302

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230510

R150 Certificate of patent or registration of utility model

Ref document number: 7278952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150